Certolizumab pegol for induction of remission in Crohn's disease

Clicks: 333
ID: 111310
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Moderate certainty evidence suggests that CZP is effective for induction of clinical remission and clinical response in participants with active CD patients. It is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small d …
Reference Key
h2019thecertolizumab Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yamazaki H;So R;Matsuoka K;Kobayashi T;Shinzaki S;Matsuura M;Okabayashi S;Kataoka Y;Tsujimoto Y;Furukawa TA;Watanabe N;;
Journal The Cochrane database of systematic reviews
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/31476018/
Keywords
systematic review National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine Remission Induction randomized controlled trials as topic Antibodies Monoclonal Humanized / therapeutic use* pmid:31476018 pmc6718195 doi:10.1002/14651858.cd012893.pub2 hajime yamazaki ryuhei so norio watanabe certolizumab pegol / therapeutic use* crohn disease / drug therapy* immunologic factors / therapeutic use induction chemotherapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.